GraftLife AB
559194-2163ActiveDeveloping patented ex-vivo perfusion technology to increase transplantable kidneys globally.
MedTech/Biotechnology Companyuglkscience.com
Yleiskatsaus
- 4
- Työntekijät
- 813t SEK
- Liikevaihto
- 2019
- Perustettu
Avainpäättäjät
Magnus Nilsson
CEO
@uglkscience.com
Kuvaus
UGLK Science AB is a Swedish biotechnology company focused on solving the critical shortage of transplantable donor kidneys. They have developed a patented ex-vivo kidney perfusion system designed for the reconditioning and evaluation of organs. This innovative system comprises a durable perfusion m...
Tunnisteet
B2BHealthTech